Common Contracts
2 similar Clinical Trial Agreement contracts
ContractClinical Trial Agreement • November 24th, 2021
CLINICAL TRIAL AGREEMENT This CLINICAL TRIAL AGREEMENT (the“Agreement”) is effective on the day of the publishing in accordance with the Act no. 340/2015 Coll. On the Register of Contracts (the “Effective Date”), by and between Fakultní nemocnice Olomouc located at I.P. Pavlova 185/6, 779 00 Olomouc, Czech Republic, represented by Prof. MUDr. Roman Havlík, PhD., director, IČO (Company ID): 00098892 (the “Institution”), XXXXXXXXXXXX, an employee of the Institution, acting within the scope of his/her employment, located at xxxxxxxxxxxx, who shall serve as the principal investigator (“Investigator”) for the Study as defined below , and Exelixis, Inc., located at 1851 Harbor Bay Parkway, Alameda, CA 94502, U.S.A.,U.S. Federal Tax ID:: 04-3257395 (the “Sponsor”). The Institution and the Investigator may be collectively referred to as the “Site”. The Investigator and certain Study Team Members (defined below) have entered into a separate agreement with Sponsor. For clarity, Investigator and
ContractClinical Trial Agreement • April 12th, 2021
CLINICAL TRIAL AGREEMENT This CLINICAL TRIAL AGREEMENT (the“Agreement”) is effective on the day of the publishing in accordance with the Act no. 340/2015 Coll. On the Register of Contracts (the “Effective Date”), by and between Fakultní nemocnice Olomouc located at I.P. Pavlova 185/6, 779 00 Olomouc, Czech Republic, represented by Prof. MUDr. Roman Havlík, PhD., director, IČO (Company ID): 00098892 (the “Institution”), XXXXXXXXXXXXX, an employee of the Institution, acting within the scope of his/her employment, located at xxxxxxxxxxx, who shall serve as the principal investigator (“Investigator”) for the Study as defined below , and Exelixis, Inc., located at 1851 Harbor Bay Parkway, Alameda, CA 94502, U.S.A.,U.S. Federal Tax ID:: 04-3257395 (the “Sponsor”). The Institution and the Investigator may be collectively referred to as the “Site”. xxxxxxxxxxxxxxxxxx 1. STATEMENT OF WORK. (a) Under a special Power of Attorney issued on 24 April 2020, Sponsor has appointed and authorized Pharma
